GLP1R and metabolic dysfunction-associated steatohepatitis: SUSTAIN-3, Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes; RCT, randomized controlled trial; ER, extended release; HbA1c, glycated hemoglobin; GI AEs, gastrointestinal adverse effects; GLP-1 RA, glucagon-like peptide-1 receptor agonist